ArticleNature medicine2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.
Abstract read
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 5 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.Bone marrow transplantation · 2025Guideline
- Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review.Rheumatology international · 2025Pooled it
- Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.Nature medicine · 2024Pooled it
- Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation.Blood cancer journal · 2025Trial
- Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms.Blood advances · 2026Article
- Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies.Clinical pharmacology and therapeutics · 2026Article
- Cardiotoxicity of T cell immunotherapies.Nature reviews. Cardiology · 2026Review
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia.Molecular therapy. Oncology · 2026Review
- Adoptive T-cell therapies in the clinic.Bioengineering & translational medicine · 2026Review
- Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected cases.Gene therapy · 2026Article
- CAR T-cells in hematologic malignancies: Advances, challenges, and future directions.iScience · 2026Review
- Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.Cancer research · 2026Review
- Data-informed optimization of CAR T-cell therapy long-term follow-up.Journal for immunotherapy of cancer · 2026Article
- Memory programming and new manufacturing paradigms in CAR-T cell therapy.Cancer gene therapy · 2026Review
- Large-scale generation of iNK and CAR-iNK cells from CD34Nature biomedical engineering · 2026Article
- Immunogenicity of Gene and Cell Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Cell therapy strategies for organ regeneration.BMC medicine · 2026Review
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Bruce L LevineCenter for Cellular Immunotherapies and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA. levinebl@pennmedicine.upenn.edu.ORCID 0000-0001-6971-8465
Marcelo C PasquiniDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
John E ConnollyParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
David L PorterCell Therapy and Transplant, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael P GustafsonDepartment of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Phoenix, AZ, USA.ORCID 0000-0002-5514-7072
Jaap J BoelensTransplantation and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2232-6952
Edwin M HorwitzDepartment of Pediatrics, Aflac Cancer and Blood Disorders Center, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-3751-4027
Stephan A GruppDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8030-7595
Marcela V MausCellular Immunotherapy Program, Mass General Cancer Center and Harvard Medical School, Cambridge, MA, USA.ORCID 0000-0002-7578-0393
Frederick L LockeDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0001-9063-6691
Fabio CiceriUniversity Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute Milano, Milan, Italy.ORCID 0000-0003-0873-0123
Annalisa RuggeriHematology and BMT unit, IRCCS San Raffaele scientific institute, Milano, Italy.
John SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.ORCID 0000-0001-6819-3476
Helen E HeslopCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-7049-7698
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute and Departments of Pediatrics and Medicine, Stanford University, Palo Alto, CA, USA.ORCID 0000-0001-6323-4304
Carl H JuneCenter for Cellular Immunotherapies and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0241-3557
Anna M SuredaClinical Hematology Department, Institut Català d'Oncologia - L'Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
Miguel-Angel PeralesAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5910-4571
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MTissue ResourceP50CA126752 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MALCOLM K. BRENNER, HELEN E HESLOP · 2007 to 2026
$51.4MDefining and overcoming intrinsic T cell dysfunction to enable pediatric immunotherapyU01CA232361 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI GRUPP, STEPHAN A., WEBER, EVAN WILLIAM · 2019 to 2019
$3.7MNCI NIH HHS P30 CA016520NCI NIH HHS P50 CA126752NCI NIH HHS U01 CA232361NCI NIH HHS U24 CA076518
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hematologic NeoplasmsLymphoma, B-CellReceptors, Chimeric AntigenCell- and Tissue-Based TherapyHumansImmunotherapy, AdoptiveReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.